
Sign up to save your podcasts
Or


Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet Group5
11 ratings
Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

139 Listeners

135 Listeners

325 Listeners

498 Listeners

64 Listeners

101 Listeners

37 Listeners

6 Listeners

130 Listeners

112,593 Listeners

20 Listeners

1,148 Listeners

21 Listeners

0 Listeners

0 Listeners

2 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

0 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

59 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners